4Greinix HT,Fae I,Schneider B,et al.Impact of HLA class Ⅰ high-resolution mismatches on chronic graft-versus-host disease and survival of patients giren hematopoietic stem cell grafts from unrelated donors[J].Bone Marrow Transplantation,2005,35(1):57
3O′Rourke ME, High K. Diagnosing graft versus host disease. Clin J Oncol Nurs,2000;4(1):47-48
4Cooper DL. HLA matching for hematopoietic stem-cell transplants. N Engl J Med,2002;346(16):1251-1252
5Van der Meer A, Allebes WA, Paardekooper J.HLA-C mismatches induce strong cytotoxic T-cell reactivity in the presence of an additional DRB/DQB mismatch and affect NK cell-mediated alloreactivity. Transplantation,2001;72(5): 923-929
6Visentainer JE, Lieber SR, Persoli LB,et al. Correlation of mixed lymphocyte culture with chronic graft-versus-host disease following allogeneic stem cell transplantation.Braz J Med Biol Res,2002;35(5):567-572
7Henslee-Downey P J. Allogeneic transplantation across major HLA barriers.Best Pract Res Clin Haematol,2001;14(4):741-754
8Chao NJ.Progress in graft-versus-host disease.J Hematother Stem Cell Res,2000;9(3):295-296
1Heuer L, Blumenberg D. Management of bleeding in multi-trans- fused patient with positive HLA class I allo-antibodies and throm- bocytopenia associated with platelet dysfunction refractory to trans- fusion of cross-matched platelets. Blood Coagul Fibrinolysis,2005, 16(4) :287-290.
2Vassallo RR. Recognition and management of antibodies to human platelet antigens in platelet transfusion-refractory patients, Immuno- hematology. 2009,25 (3) : 119-124.
3Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haema- tol.2008.142 ( 3 ) : 348 -360.
4Fabris F,Soini B,Sartori R,et al. Clinical and laboratory factors that affect the post-transfusion platelet increment. Transfus Sei, 2000.23( 1 ) :63-68.
5Davoren A, McParland P, C Rowley J, et al. Antenatal screening for human platelet antigen 21 a:results of a prospective study at a large maternity hospital in Ireland. B JOG,2003,110 ( 5 ) :492 -496.
